Company Description
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.
It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting.
The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus.
In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings.
Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
| Country | United States |
| Founded | 2013 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 115 |
| CEO | Dwight Egan |
Contact Details
Address: 2401 S. Foothill Drive, Suite D Salt Lake City, Utah 84109 United States | |
| Phone | 801 438 1036 |
| Website | co-dx.com |
Stock Details
| Ticker Symbol | CODX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001692415 |
| CUSIP Number | 189763204 |
| ISIN Number | US1897632048 |
| Employer ID | 46-2609396 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dwight H. Egan | Chairman, Chief Executive Officer and President |
| Richard David Abbott | President |
| David Nielsen | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2026 | 8-K | Current Report |
| Dec 30, 2025 | 8-K | Current Report |
| Dec 19, 2025 | 424B5 | Filing |
| Dec 5, 2025 | 8-K | Current Report |
| Nov 13, 2025 | 10-Q | Quarterly Report |
| Nov 13, 2025 | 8-K | Current Report |
| Nov 13, 2025 | SCHEDULE 13G | Filing |
| Nov 10, 2025 | DEF 14A | Other definitive proxy statements |
| Oct 31, 2025 | PRE 14A | Other preliminary proxy statements |
| Oct 30, 2025 | SCHEDULE 13G/A | Filing |